- Genetic medicine luminaries launch new center for personalized therapiesA team of veteran scientists from elite institutions has come together to form a new center dedicated to the crafting of personalized genetic medicines, adding to the growing list of similar effort…Fierce Biotech · 7d ago↗ source
- 2026 IPO class blooms again as BlossomHill, Latigo set sights on NasdaqEighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.BioSpace · 7d ago↗ source
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…